Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair loss in men is primarily caused by androgenetic alopecia, with treatments like finasteride and dutasteride often recommended. Other causes include stress, nutritional deficiencies, medications, and scalp infections.

The conversation discusses whether to get blood work before starting finasteride, with opinions varying on its necessity. One user reported developing gynecomastia after using finasteride, despite trying Anastrozole to manage estradiol levels.

Dutasteride mesotherapy is discussed as a potentially effective hair loss treatment with no sexual side effects, requiring less frequent application than daily pills. However, it is not widely popular due to limited availability, high cost, and skepticism about its effectiveness.

A user experienced significant hair loss after taking birth control and sought medical advice. They were advised to consider spironolactone and minoxidil for treatment, and to consult a dermatologist for further evaluation.

VDPHL01, an extended-release oral minoxidil tablet, showed promising results in improving hair coverage for 79 to 86% of men in a trial, with fewer side effects compared to standard doses. Many users prefer oral minoxidil over topical due to ease of use and fewer side effects, especially for those with pets.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.

Hair loss is linked to scalp fibrosis and tension, which result from chronic mechanical stress and androgenic signaling. Treatments include blocking androgens with finasteride, promoting hair growth with topical minoxidil, and improving scalp mobility through exercises.

A user applied minoxidil for hair loss and worried about its toxicity to cats after their cat drank from a water fountain they touched. After consulting a vet and pet poison control, they were reassured that the exposure was not enough to harm the cat, and others advised using gloves and being cautious in the future.

The conversation discusses the complexity of reversing hair loss and the need for a treatment that specifically targets DHT levels without affecting other bodily functions. It mentions finasteride as a current treatment but highlights the desire for a solution that works solely on the scalp.

The user started a hair loss treatment with finasteride and minoxidil, then switched to dutasteride and minoxidil, experiencing increased body hair and reduced alcohol tolerance. They plan to get a hair transplant in 12 months and have received compliments on their eyelashes.

The user is considering taking finasteride every other day to reduce side effects like decreased libido and erection issues. Suggestions include reducing the dosage, switching to topical treatments like dutasteride, or consulting a doctor.

The user reported positive results using KX-826 0.5% twice daily for hair loss, noting progress in the temple area with no systemic side effects. They avoided finasteride and minoxidil due to concerns about side effects and inconvenience, respectively, and used ketoconazole shampoo for seborrheic dermatitis.

A 20-year-old has been using topical 5% minoxidil for 12 months and started 1 mg of finasteride daily nearly 6 months ago, noticing thicker hair and new growth. Despite some initial side effects, they report no current issues and are considering adding tretinoin to their regimen.

Zohran Mamdani is using oral minoxidil for hair loss. There is discussion about the importance of using a DHT blocker like finasteride alongside minoxidil.

Finasteride can cause gynecomastia due to increased estrogen from reduced DHT conversion, which some users manage by losing weight and taking supplements like DIM and calcium D-glucarate. Users discuss various experiences with finasteride, dutasteride, and minoxidil, noting side effects and strategies to mitigate them, including switching medications and considering surgery.

The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.

The user is experiencing hair loss despite using estradiol, bicalutamide, dutasteride, and topical minoxidil. They stopped minoxidil temporarily, which worsened their condition, and are considering oral minoxidil but are concerned about side effects and cost.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

Hair loss is mainly influenced by genetics and DHT sensitivity. Treatments discussed include minoxidil, oral minoxidil, and finasteride.

A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.

DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.

The conversation discusses preventing hair loss during detransitioning, with suggestions to use finasteride or dutasteride as DHT blockers. The user is also considering rosemary oil and monitoring testosterone levels.

The user has high DHT levels despite using dutasteride, which may not be effective due to potential damage or spoilage. They are considering a hair transplant if DHT levels don't decrease after two years.

Many users have maintained their hair using finasteride, with some also using minoxidil or dutasteride, reporting minimal side effects. Opinions vary on the necessity of DHT, with some users arguing its importance beyond puberty, while others believe it is unnecessary and that finasteride and dutasteride are safe and effective for hair maintenance.

Dairy may contain DHT precursors that could affect hair loss and prostate health, with some users noting reduced hair shedding after eliminating dairy. Individual responses to dairy and DHT blockers vary, with some attributing hair health to diet changes and others seeing no impact.

The conversation discusses using oral spironolactone for hair loss in males when 5ari blockers fail. Concerns are raised about spironolactone's side effects, and alternatives like pyrilutamide and breezula are suggested.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

Hair loss treatments are being tested on mice, with methods like minoxidil and stem cell therapy showing promising results. However, human trials are still years away, leading to humorous frustration about mice benefiting first.